584 related articles for article (PubMed ID: 23345613)
1. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
Hwang IC; Bruera E; Park SM
Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl nasal spray (Lazanda) for pain.
Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
8. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
9. Recent development in therapeutics for breakthrough pain.
Davis MP
Expert Rev Neurother; 2010 May; 10(5):757-73. PubMed ID: 20420495
[TBL] [Abstract][Full Text] [Related]
10. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
[TBL] [Abstract][Full Text] [Related]
11. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Fine PG; Narayana A; Passik SD
Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
[TBL] [Abstract][Full Text] [Related]
12. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Borgbjerg FM; Rosenberg J
Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
14. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
16. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
Shinjo T; Okada M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744
[TBL] [Abstract][Full Text] [Related]
17. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
[TBL] [Abstract][Full Text] [Related]
18. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
